RxDoctor Payments DataLook up a doctor →

Jason Franks, MD

Internal Medicine · Magnolia, ARNPI 1407848922

Payments from drug & device makers

$7,063in general payments, 2019–2025

Across 480 payments — averaging $14.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$732
  • Lilly USA, LLC$645
  • Pfizer$541
  • Novo Nordisk$537
  • Astellas Pharma US Inc$436
  • Amgen$366
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$6,98799%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,063 in reported general payments places this provider in the 90th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$693,521
Medicare patients
1,071
Services billed
17,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban273$189,448
OzempicSemaglutide56$54,910
EntrestoSacubitril/Valsartan40$39,160
MounjaroTirzepatide36$36,728
JanuviaSitagliptin Phosphate45$33,441
JardianceEmpagliflozin32$29,043
XareltoRivaroxaban36$27,793
FarxigaDapagliflozin Propanediol40$24,002
TrulicityDulaglutide19$22,015
Tresiba Flextouch U-200Insulin Degludec34$20,403
MyrbetriqMirabegron37$16,743
Tresiba Flextouch U-100Insulin Degludec25$15,618
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,296
LinzessLinaclotide12$11,058
Aimovig AutoinjectorErenumab-Aooe13$10,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$541$192,095286 claims
Lilly USA, LLCMounjaro, Trulicity$645$58,74355 claims
Novo NordiskOzempic$537$54,91056 claims
NovartisEntresto$245$39,16040 claims
MerckJanuvia, Janumet$234$36,54056 claims
Boehringer IngelheimJardiance, Tradjenta$236$35,99346 claims
AstraZenecaFarxiga, Brilinta$354$33,35361 claims
Johnson & JohnsonXarelto$308$27,79336 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$327$22,89346 claims
Astellas Pharma US IncMyrbetriq, Vesicare$436$21,29249 claims
AbbVieLinzess, Synthroid$732$17,28983 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Magnolia

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →